These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 7854772

  • 1. Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies.
    Suzuki M, Ohwada M, Sato I, Nagatomo M.
    Oncology; 1995; 52(2):128-33. PubMed ID: 7854772
    [Abstract] [Full Text] [Related]

  • 2. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer.
    Xu FJ, Ramakrishnan S, Daly L, Soper JT, Berchuck A, Clarke-Pearson D, Bast RC.
    Am J Obstet Gynecol; 1991 Nov; 165(5 Pt 1):1356-62. PubMed ID: 1957862
    [Abstract] [Full Text] [Related]

  • 3. Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies.
    Baiocchi G, Kavanagh JJ, Talpaz M, Wharton JT, Gutterman JU, Kurzrock R.
    Cancer; 1991 Feb 15; 67(4):990-6. PubMed ID: 1825026
    [Abstract] [Full Text] [Related]

  • 4. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.
    van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Bast RC, Hacker NF.
    Cancer; 2001 Dec 01; 92(11):2837-44. PubMed ID: 11753957
    [Abstract] [Full Text] [Related]

  • 5. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
    Suzuki M, Ohwada M, Aida I, Tamada T, Hanamura T, Nagatomo M.
    Obstet Gynecol; 1993 Dec 01; 82(6):946-50. PubMed ID: 8233270
    [Abstract] [Full Text] [Related]

  • 6. Clinical value of a new serum tumor marker, CA125II, in gynecologic disease: comparison with CA125.
    Tamakoshi K, Kikkawa F, Hasegawa N, Ishikawa H, Mizuno K, Kawai M, Tomoda Y.
    Gynecol Obstet Invest; 1995 Dec 01; 39(2):125-9. PubMed ID: 7737582
    [Abstract] [Full Text] [Related]

  • 7. [Macrophage-colony stimulating factor and ovarian cancer].
    Menditto A, Piscittelli V, Cassese F, Balbi GC, Balbi C, Cardone A.
    Minerva Ginecol; 1999 Dec 01; 51(7-8):261-4. PubMed ID: 10536419
    [Abstract] [Full Text] [Related]

  • 8. Elevation of multiple serum markers in patients with stage I ovarian cancer.
    Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, Soper JT, Clarke-Pearson DL, Oram DH, Bast RC.
    J Natl Cancer Inst; 1993 Nov 03; 85(21):1748-51. PubMed ID: 8411259
    [Abstract] [Full Text] [Related]

  • 9. Macrophage colony-stimulating factor as a tumor marker for squamous cell carcinoma of the head and neck.
    Kuropkat C, Dünne AA, Plehn S, Ossendorf M, Herz U, Renz H, Werner JA.
    Tumour Biol; 2003 Nov 03; 24(5):236-40. PubMed ID: 15001836
    [Abstract] [Full Text] [Related]

  • 10. The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma.
    Smith HO, Anderson PS, Kuo DY, Goldberg GL, DeVictoria CL, Boocock CA, Jones JG, Runowicz CD, Stanley ER, Pollard JW.
    Clin Cancer Res; 1995 Mar 03; 1(3):313-25. PubMed ID: 9815987
    [Abstract] [Full Text] [Related]

  • 11. Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers.
    Sidorkiewicz I, Zbucka-Krętowska M, Zaręba K, Lubowicka E, Zajkowska M, Szmitkowski M, Gacuta E, Ławicki S.
    BMC Cancer; 2019 Apr 29; 19(1):398. PubMed ID: 31035945
    [Abstract] [Full Text] [Related]

  • 12. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML.
    Clin Cancer Res; 1997 Jun 29; 3(6):999-1007. PubMed ID: 9815777
    [Abstract] [Full Text] [Related]

  • 13. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
    Riisbro R, Stephens RW, Brünner N, Christensen IJ, Nielsen HJ, Heilmann L, von Tempelhoff GF.
    Gynecol Oncol; 2001 Sep 29; 82(3):523-31. PubMed ID: 11520150
    [Abstract] [Full Text] [Related]

  • 14. Cytokeratin fragment 21-1 in gynecologic malignancy: comparison with cancer antigen 125 and squamous cell carcinoma-related antigen.
    Inaba N, Negishi Y, Fukasawa I, Okajima Y, Ota Y, Tanaka K, Matsui H, Iwasaki H, Sudo H, Tanaka N.
    Tumour Biol; 1995 Sep 29; 16(6):345-52. PubMed ID: 7569681
    [Abstract] [Full Text] [Related]

  • 15. Serum sICAM-1 (soluble intercellular adhesion molecule-1) and M-CSF (macrophage colony-stimulating growth factor) throughout monitoring of 34 non-serous ovarian cancers.
    Callet N, Delaunay J, Pichon MF.
    Eur J Gynaecol Oncol; 2000 Sep 29; 21(2):135-40. PubMed ID: 10843471
    [Abstract] [Full Text] [Related]

  • 16. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.
    Skates SJ, Horick N, Yu Y, Xu FJ, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Zhang Z, Bast RC.
    J Clin Oncol; 2004 Oct 15; 22(20):4059-66. PubMed ID: 15381683
    [Abstract] [Full Text] [Related]

  • 17. [The plasma levels and diagnostic utility of granulocyte colony stimulating factor (G-CSF) and macrophage - colony stimulating factor (M-CSF) in ovarian cancer patients].
    ławicki S, Czygier M, Gacuta-Szumarska E, Knapp P, Szmitkowski M.
    Pol Merkur Lekarski; 2006 Nov 15; 21(125):465-8. PubMed ID: 17345841
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer.
    Olt G, Soper J, Ramakrishnan S, Xu F, Berchuck A, Clarke-Pearson D, Dodge R, Bast RC.
    Am J Obstet Gynecol; 1996 Apr 15; 174(4):1316-9. PubMed ID: 8623863
    [Abstract] [Full Text] [Related]

  • 20. Comparative evaluation of plasma levels and diagnostic values of macrophage-colony stimulating factor in patients with breast cancer and benign tumors.
    Ławicki S, Czygier M, Bedkowska E, Wojtukiewicz M, Szmitkowski M.
    Pol Arch Med Wewn; 2008 Sep 15; 118(9):464-9. PubMed ID: 18846980
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.